Getinge (OTCMKTS:GNGBY) vs. GeneDx (NASDAQ:WGS) Head to Head Comparison

GeneDx (NASDAQ:WGS – Get Free Report) and Getinge (OTCMKTS:GNGBY – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility and Risk

GeneDx has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Getinge has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Insider and Institutional Ownership

61.7% of GeneDx shares are owned by institutional investors. 25.2% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares GeneDx and Getinge’s net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for GeneDx and Getinge, as reported by MarketBeat.

GeneDx currently has a consensus price target of $90.86, suggesting a potential upside of 45.67%. Given GeneDx’s stronger consensus rating and higher possible upside, equities analysts clearly believe GeneDx is more favorable than Getinge.

Earnings and Valuation

This table compares GeneDx and Getinge”s gross revenue, earnings per share and valuation.

Getinge has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Getinge, indicating that it is currently the more affordable of the two stocks.

About GeneDx

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About Getinge

(Get Free Report)

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions. The company also provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, and drainage solutions; and operating room infrastructure equipment, anesthesia, advanced patient monitoring, operating room management, and operating room integration solutions. In addition, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices; bioreactor systems, DPTE systems, Getinge isolators, terminal sterilization products, and sterilizers; and vivarium, biohazardous materials handling solutions, labware cleaning and sterilization, upstream bioprocessing, and bioreactor preparation solutions. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.